<DOC>
	<DOCNO>NCT00002531</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Randomized phase II trial study effectiveness various combination chemotherapy regimens treat patient acute lymphocytic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Adults With Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Develop risk-adapted therapy patient low-risk , high-risk , T-cell , B-cell acute lymphocytic leukemia ( ALL ) . II . Determine complete remission rate patient treat follow strategy : increase dos cyclophosphamide induction reinduction , early use high-dose cytarabine plus mitoxantrone ( high-risk patient ) , increased dos methotrexate ( B-cell ALL patient ) . III . Determine duration remission survival patient risk group treat intensified consolidation subtype-specific chemotherapy . IV . Compare effect intensify vs conventional maintenance therapy patient risk group . OUTLINE : This randomize , multicenter study . Patients assign 1 4 treatment group base disease status . Patients group 1-3 large leukemic cell mass , particular WBC great 25,000/mm3 and/or mark organomegaly , receive preinduction therapy comprise oral prednisolone ( PRDL ) 3 time day day 1-7 vincristine ( VCR ) IV day 1 . Group 1 ( low-risk acute lymphocytic leukemia ( ALL ) ) : First induction therapy : Patients receive oral PRDL 3 time day day 1-7 week 1-4 , asparaginase ( ASP ) IV 30 minute day 1-7 week 3 4 , VCR IV daunorubicin IV 30 minute day 1 week 1-4 , methotrexate ( MTX ) IT day 1 week 1 . Patients achieve complete remission ( CR ) first induction therapy proceed first consolidation therapy group 1 . Second induction therapy : Patients receive oral cyclophosphamide ( CTX ) IV day 1 week 5 , 7 , 9 ; cytarabine ( ARA-C ) IV 1 hour subcutaneously day 3-6 MTX IT day 3 week 5-8 ; oral mercaptopurine ( MP ) day 1-7 week 5-8 day 1 week 9 . Patients achieve CR second induction therapy undergo prophylactic cranial irradiation 5 day week 2.4 week . Patients achieve CR second induction therapy proceed group 3 . First consolidation therapy : Patients receive high-dose MTX IV continuously leucovorin calcium ( CF ) rescue day 1 , ASP IV 1 hour day 2 , oral MP day 1-5 week 13 15 ; teniposide ( VM-26 ) IV 1 hour ARA-C IV 1 hour day 1-5 week 17 . Triple intrathecal therapy ( TIT ) comprise MTX , ARA-C , dexamethasone ( DM ) also administer day 1 week 17 . First reinduction therapy : Patients receive oral PRDL three time day day 1-7 VCR IV doxorubicin ( DOX ) IV 30 minute day 1 week 21-24 , TIT day 1 week 21 . Second reinduction therapy : Patients receive CTX IV TIT day 1 week 25 , ARA-C IV 1 hour day 3-6 oral thioguanine ( TG ) day 1-7 week 25 26 . Second consolidation therapy : Patients receive oral MP daily oral MTX weekly week 29-32 , 34-38 , 40-44 , 46-50 , 52 ; high-dose MTX , CF rescue , ASP first consolidation therapy week 33 45 ; VM-26 , ARA-C , TIT first consolidation therapy week 39 51 . Group 2 ( T-cell ALL without mediastinal involvement ) : First induction therapy : Patients receive treatment first induction therapy group 1 . Patients residual tumor great 2 cm first induction therapy also undergo mediastinal radiotherapy 5 day week 2.4-2.7 week concurrently prophylactic cranial irradiation . Second induction therapy : Patients receive treatment second induction therapy group 1 . First consolidation therapy : Patients receive high-dose ARA-C IV 3 hour every 12 hour day 1-4 mitoxantrone ( DHAD ) IV 30 minute day 3-5 week 13 ; high-dose MTX , CF rescue , ASP , MP first consolidation therapy group 1 week 17 . First reinduction therapy : Patients receive treatment first reinduction therapy group 1 . Second reinduction therapy : Patients receive treatment second reinduction therapy group 1 . Second consolidation therapy : Patients receive MP MTX second consolidation therapy group 1 ; CTX IV , ARA-C IV continuously , TIT day 1 week 33 45 ; VM-26 , ARA-C , TIT first consolidation therapy group 1 week 39 51 . Group 3 ( high-risk ALL ) : First induction therapy : Patients receive treatment first induction therapy group 1 . Second induction therapy : Patients receive CNS-effective chemotherapy comprise high-dose ARA-C every 12 hour day 1-4 DHAD IV 30 minute day 3-5 week 6 . First consolidation therapy : Patients receive high-dose MTX , CF rescue , ASP first consolidation therapy group 1 ; CTX , ARA-C , TIT second consolidation therapy group 2 week 17 . First reinduction therapy : Patients receive treatment first reinduction therapy group 1 . Second reinduction therapy : Patients receive treatment second reinduction therapy group 1 . Second consolidation therapy : Patients receive MP MTX second consolidation therapy group 1 ; treatment second induction therapy group 3 week 33 ; high-dose MTX , CF rescue , ASP , MP first consolidation therapy group 1 week 39 ; CTX , ARA-C , TIT second consolidation therapy group 2 week 45 ; VM-26 , ARA-C , TIT first consolidation therapy group 1 week 51 . Groups 1-3 : Patients age 15 50 , achieve first CR , suitable donor undergo allogeneic bone marrow transplantation . Patients age 40 undergo bone marrow transplantation match unrelated donor . Patients Philadelphia chromosome/bcr-abl positive disease suitable donor undergo purge autologous peripheral blood stem cell transplantation instead reinduction therapy first CR . CNS therapy : Patients CNS disease entry receive TIT 2 3 time weekly begin immediately upon diagnosis continue 5 dos blast clear CSF . Patients group 1 2 undergo irradiation entire neuraxis 5 day week 2.7-3.2 week second induction therapy . Maintenance therapy : After completion 1 year treatment group 1 , 2 , 3 , patient randomize 1 2 treatment arm . Arm I : Patients receive MP daily MTX weekly odd-numbered month month 13-30 ; CTX , ARA-C , TIT second consolidation therapy group 2 month 14 , 20 , 26 ; VM-26 , ARA-C , TIT first consolidation therapy group 1 month 16 , 22 , 28 ; high-dose MTX , CF rescue , ASP first consolidation therapy group 1 month 18 , 24 , 30 . Arm II : Patients receive MP plus MTX second consolidation therapy group 1 continuously TIT every 2 month month 13-30 . Group 4 ( B-cell ALL ) : Pretreatment : Patients age 50 receive CTX IV 1 hour oral PRDL 3 time day day 1-5 . Patients age 50 receive CTX IV oral DM day 1 , 3 , 5 . Treatment : Patients receive alternate therapy block A B . Block A therapy consist VCR IV , MTX IV continuously , CF rescue day 1 ; ifosfamide IV 1 hour oral DM day 1-5 ; VM-26 IV 1 hour ARA-C IV 1 hour every 12 hour day 4 5 ; TIT day 1 5 . Block B therapy consist VCR IV , MTX IV continuously , CF rescue day 1 ; CTX IV 1 hour oral DM day 1-5 ; DOX IV 15 minute day 4 5 ; TIT day 1 5 . Blocks A B continue every 3 week total 6 course . Patients achieve CR 3 course develop disease progression time may optionally receive vindesine , ARA-C , etoposide , DM . Patients CNS disease undergo craniospinal irradiation 2 course systemic chemotherapy ( block A B therapy ) . Patients receive TIT 2-3 time weekly CSF clear block A therapy response unsatisfactory . PROJECTED ACCRUAL : Approximately 700 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Teniposide</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis lowrisk acute lymphocytic leukemia ( ALL ) ( common ALL preBcell ) Must meet 1 follow 2 condition : Age 51 65 meet follow criterion : No mediastinal mass No Tcell Bcell disease Age 15 50 meet follow criterion : Philadelphia chromosome ( Ph ) negative bcrabl negative Initial WBC le 30,000/mm3 OR Diagnosis Tcell ALL without mediastinal involvement Age 15 50 OR Diagnosis highrisk ALL ( common ALL preBcell ) Age 15 50 meet 1 follow criterion : Ph positive bcrabl positive PrepreBcell disease , i.e. , ( 4 ; 11 ) Initial WBC great 30,000/mm3 OR Diagnosis Bcell ALL PATIENT CHARACTERISTICS : Age : See Disease Characteristics 15 65 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : No renal failure Cardiovascular : No cardiomyopathy Other : HIV1 HIV2 negative No severe psychiatric disease PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytostatic drug except vincristine Endocrine therapy : Prior corticosteroid allow Radiotherapy : Not specify Surgery : Not specify Other : No 2 week prior therapy No prior cytostatic drug</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>T-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B adult acute lymphoblastic leukemia</keyword>
</DOC>